Just a clarification @zilliqua: Atomo does not "produce" antigen tests; they procure them from Access Bio.
But yes, supply on other fronts has been noted as a key issue, hence the ongoing investment in infrastructure, blister machine and the like.
In a recent update, Atomo noted that their current production capacity (as well as the customer-centered nature of their product) has made them a more attractive option for multinational companies.
Atomo Lack Capacity to Suppy, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 497908 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 67200 | 3 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable